Related Experiment Videos
Vinorelbine (Navelbine): a third-generation vinca alkaloid
1Don Monti Division of Oncology, North Shore University Hospital, Manhasset, New York, USA.
Cancer Investigation
|January 1, 1997
Summary
Vinorelbine, a vinca alkaloid derivative, shows significant antitumor activity and is a promising cancer treatment. While it exhibits hematological toxicity, its efficacy against various tumors makes it a valuable therapeutic option.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Vinca alkaloids are established antineoplastic agents inhibiting microtubule polymerization.
- These compounds exhibit broad-spectrum activity against human and animal tumors.
- Vinorelbine is a semisynthetic analog developed to improve upon older vinca alkaloids.
Purpose of the Study:
- To evaluate the clinical efficacy and toxicity profile of vinorelbine.
- To compare vinorelbine's preclinical activity and toxicity with older vinca alkaloids.
- To assess vinorelbine's antitumor activity in diseases responsive to vinca alkaloids.
Main Methods:
- Clinical trials were conducted to assess vinorelbine's efficacy and safety.
- Preclinical models were used to evaluate cytotoxic activity and neurotoxicity.
- Pharmacokinetic studies investigated vinorelbine clearance in human subjects.
Main Results:
- Vinorelbine demonstrated significant antitumor activity in various cancers.
- Hematological toxicity was the predominant adverse effect observed in humans.
- Preclinical data suggested lower neurotoxicity and higher cytotoxic activity compared to older analogs.
Conclusions:
- Vinorelbine is an effective antineoplastic agent with a notable spectrum of activity.
- Its clinical use is associated with manageable hematological toxicity.
- Vinorelbine represents a valuable therapeutic option within the vinca alkaloid class for cancer treatment.